Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

STAAR Surgical Says That No Acquisition Proposals Have Been Received From Any Party Other Than Alcon; Alcon Is Paying STAAR Stockholders A 59% Premium To STAAR's 90-Day Volume Weighted Average Price As Of August 4, 2025, Representing Compelling, Certain, And Immediate Cash Value

Author: Benzinga Newsdesk | October 16, 2025 04:18pm

STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement:

Broadwood Partners' statements and assertions regarding interest in STAAR are misleading and distort the truth. Broadwood is misrepresenting introductory emails as offers to acquire STAAR. As previously disclosed, the communications from Party A and B were not offers and contained no information relating to valuation, timing, diligence requirements, financing capability, transaction structure, or other terms.1

Similarly, as disclosed in STAAR's Form 8-K filing with the SEC on October 14, 2025, a representative of a privately-owned company ("Party C") also emailed STAAR on April 7, 2025. Since the Form 8-K filing, Party C has confirmed to STAAR that "the outreach was an introductory email and was not intended as a proposal." The email was not followed up on by Party C.

The facts remain:

  • Despite Broadwood's assertions, STAAR has not received any proposal to acquire the Company other than from Alcon, including during the 45-day "window shop" period.
  • The outreach from Parties A, B, and C were not offers.
  • Alcon is paying STAAR stockholders a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) as of August 4, 2025, representing compelling, certain, and immediate cash value.

We urge all STAAR stockholders not to be misled by Broadwood. STAAR is confident that the Alcon transaction maximizes value for STAAR stockholders, is the only merger transaction available to the Company and if it is not approved, the value of your shares is at risk of declining substantially. Time is short. The Special Meeting is fast approaching. We encourage all STAAR stockholders to vote ‘FOR' the Alcon merger on the WHITE proxy card TODAY.

STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote on the Alcon merger. Stockholders of record as of the close of business on September 12, 2025, are entitled to vote at the meeting.

The STAAR Board of Directors has unanimously approved the merger and recommended that all STAAR stockholders vote "FOR" the merger proposal on the WHITE proxy card TODAY.

Posted In: STAA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist